In one paragraphArticle in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Valeria WagnerDepartment of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Medical University of Innsbruck, Christoph-Probst-Platz 1, 6020 Innsbruck, Austria.
Michael MedererDepartment of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Medical University of Innsbruck, Christoph-Probst-Platz 1, 6020 Innsbruck, Austria.ORCID 0009-0004-5901-624X Barbara EnrichDepartment of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Medical University of Innsbruck, Christoph-Probst-Platz 1, 6020 Innsbruck, Austria.
Veronika CibulkovaDepartment of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Medical University of Innsbruck, Christoph-Probst-Platz 1, 6020 Innsbruck, Austria.ORCID 0009-0007-5416-7841 Johanna PiaterDepartment of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Medical University of Innsbruck, Christoph-Probst-Platz 1, 6020 Innsbruck, Austria.
Andreas ZollnerDepartment of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Medical University of Innsbruck, Christoph-Probst-Platz 1, 6020 Innsbruck, Austria.ORCID 0000-0001-6095-068X Rebecca Giquel-FernandesDepartment of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Medical University of Innsbruck, Christoph-Probst-Platz 1, 6020 Innsbruck, Austria.
Herbert TilgDepartment of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Medical University of Innsbruck, Christoph-Probst-Platz 1, 6020 Innsbruck, Austria.ORCID 0000-0002-4235-2579 Maria EffenbergerDepartment of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Medical University of Innsbruck, Christoph-Probst-Platz 1, 6020 Innsbruck, Austria.ORCID 0000-0002-0499-9953 Funding
Austrian Society of Gastroenterology and Hepatology Nachwuchswisschenschaftspreis 2025Austrian Society of Gastroenterology and Hepatology Wissenschaftspreis 2022Landes Tirols AI in Medicine
6 · The paper itselfAbstract
backgroundInterleukin-38 (IL-38) is an anti-inflammatory IL-1-family cytokine implicated in limiting tissue injury by its anti-inflammatory character. We evaluated the diagnostic discrimination and prognostic relevance in steatotic liver disease (SLD).
methodsWe conducted a prospective, monocentric cohort analysis of 184 patients with SLD (
findingsIL-38 concentrations were found to be higher in decompensated (
conclusionIL-38 reflects the severity of steatotic liver disease and is therefore a potentially predictive biomarker for early risk stratification and therapy monitoring.
Indexed as
BiomarkersFatty LiverInterleukinsAdultAgedFemaleHumansMaleMiddle AgedPrognosisProspective StudiesROC CurveSeverity of Illness IndexBiomarkersIL-38 protein, humanInterleukinsalcohol-associated liver disease (ALD)biomarkerhepatic decompensationIL-1 cytokine familyIL-38metabolic dysfunction-associated alcohol-related liver disease (metALD)
Identifiers
PMID41677643
PMCPMC12897045
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390